SynthesisJournal of Parkinson's disease2019
Increasing Comparability and Utility of Gut Microbiome Studies in Parkinson's Disease: A Systematic Review.
Synthesis in Journal of Parkinson's disease, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05469997 (Ketogenic Diet Interventions in Parkinson's Disease), which is not on this map. Cited by 97 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Ketogenic Diet Interventions in Parkinson's Disease: Safeguarding the Gut Microbiome
Who cites it
97 citing papers in PubMed, 4 syntheses or guidelines pooled it, 178 citations in OpenAlex.
- Alterations of Gut Microbiota and Microbial Metabolites in Parkinson's Disease: A Systematic Review.Molecular neurobiology · 2025Pooled it
- Compositional and Functional Alterations in Intestinal Microbiota in Patients with Psychosis or Schizophrenia: A Systematic Review and Meta-analysis.Schizophrenia bulletin · 2023Pooled it
- Gut bacterial profiles in Parkinson's disease: A systematic review.CNS neuroscience & therapeutics · 2023Pooled it
- Pooled it
- Pilot Clinical Trial of Fecal Microbiota Transplantation for Constipation in Parkinson's Disease.Journal of microbiology and biotechnology · 2025Trial
- Cellular and systemic modifiers of alpha-synuclein proteostasis.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2026Review
- The Influence of Gut Microbiome on Alpha-Synuclein Aggregation: Implications for Parkinson's Disease Pathogenesis.Molecular neurobiology · 2026Review
- Gut microbiota and SCFA biomarkers for early diagnosis of PD patients and differentiation of its motor subtypes.NPJ Parkinson's disease · 2026Article
- Gut bacteria composition in animal models of Parkinson's disease: a systematic review and meta-analysis.NPJ Parkinson's disease · 2026Article
- The microbiome and non-occupational human-animal interactions: a scoping review.Frontiers in public health · 2026Article
- Nutrition and the gut microbiome: a symbiotic dialogue influencing health and disease.Frontiers in nutrition · 2026Review
- Associations between gut microbiota and multiple system atrophy: a Mendelian randomization study.Journal of neurology · 2025Article
- "Recommendations for clinical study protocols for immune and inflammatory profiling in Parkinson's disease".NPJ Parkinson's disease · 2025Review
- Review
- A rationally designed microbial consortium modulates neurodegeneration in a Drosophila melanogaster model of Parkinson's disease.NPJ biofilms and microbiomes · 2025Article
- Human gut microbiome gene co-expression network reveals a loss in taxonomic and functional diversity in Parkinson's disease.NPJ biofilms and microbiomes · 2025Article
- Comparison of phage and plasmid populations in the gut microbiota between Parkinson's disease patients and controls.Scientific reports · 2025Article
- A prebiotic dietary pilot intervention restores faecal metabolites and may be neuroprotective in Parkinson's Disease.NPJ Parkinson's disease · 2025Article
- The microbiota-gut-brain axis: a potential target in the small-molecule compounds and gene therapeutic strategies for Parkinson's disease.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Review
- Advanced Membrane Simulations in Probiotics and Gut Microbiome Interaction Research: The Current Trends and Insights.Current pharmaceutical design · 2025Review
37 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gut microbiota have been studied in relation to the pathophysiology of Parkinson's disease (PD) due to the early gastrointestinal symptomatology and presence of alpha-synuclein pathology in the enteric nervous system, hypothesized to ascend via the vagal nerve to the central nervous system. Accordingly, sixteen human case-control studies have published gut microbiome composition changes in PD and reported over 100 differentially abundant taxa covering all taxonomic levels from phylum to genus or species, depending on methodology. While certain findings were replicated across several studies, various contradictory findings were reported. Here, differences in methodologies and the presence of possible confounders in the study populations are assessed for their potential to confound the results of gut microbiome studies in PD. Gut microbiome studies in PD exhibited considerable variability with respect to the study population, sample transport conditions, laboratory protocols and sequencing, bioinformatics pipelines, and biostatistical methods. To move from the current heterogeneous dataset towards clinically relevant biomarkers and the identification of putative therapeutic targets, recommendations are derived from the limitations of the available studies to increase the future comparability of microbiome studies in PD. In addition, integration of currently available data on the gut microbiome in PD is proposed to identify robust gut microbiome profiles in PD. Furthermore, expansion of the current dataset with atypical parkinsonism cohorts, prodromal and treatment-naïve de novo PD subjects, measurements of fecal microbial concentrations and multi-omics assessments are required to provide clinically relevant biomarkers and reveal therapeutic targets within the gut microbiome of PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.